Global In-Vitro Diagnostics Market Insights, Size & Growth Forecast To 2028

Global In-Vitro Diagnostics Market - By Product Type (Reagents, Instruments, and Software & Services), By Technique (Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques), By Application (Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications), and By End User (Standalone Laboratory, Hospitals, Academic & Medical Schools, Point of Care Testing, and Others)and By Region (North America, Europe, Asia Pacific, South America, and Middle East, & Africa)- Global forecast from 2021-2028

Published: Apr-2021	Report ID: HLCA2105	Pages: 1 - 218	Formats^*:
Category : Healthcare

The Global In-vitro Diagnostics market emerge the market growth owing to rising chronic diseases and development in advance technology

The global in-vitro diagnostics market size is projected to reach USD 110.0 billion by 2028 at a CAGR of 3.8% during the forecast period. With the changing lifestyle of people, there are higher requirements for disease risk prediction, health management, chronic disease management, etc. The In-vitro diagnostic market has vast room for development, especially in regions and countries with underdeveloped medical standards.

Among the types of IVD products, the localization rate of midstream products of molecular diagnosis is relatively high, and the downstream diagnosis service market is increasing. Also, information technology, big data, cloud computing, and the Internet have gradually strengthened interaction and integration with various industries and are also subverting the development model of multiple sectors.

Therefore, the traditional business model of the IVD industry is to obtain profits by selling instruments and reagent products, providing medical testing services and laboratory solutions, and the future development of the IVD industry will also usher in significant changes.

Product Overview in the Global In-vitro Diagnostics Market

Based on the product, the global In-Vitro Diagnostics market segmented into Reagents, Instruments, and Software & Services. The instrument segment has captured the highest market value in the comprehensive In-vitro diagnostics market in the forecast period from 2021-2028. It is mainly owing to the emerging need for early diagnosis of infectious diseases. Moreover, reagents will bolster the market demand for the global In-vitro diagnostics market. It is mainly owing to rising technology and convenient non-invasive device and home care kits.

Technique Overview in the Global In-vitro Diagnostics Market

Based on the technique, the global In-Vitro Diagnostics market classified into Immunodiagnostics, Hematology, Molecular Diagnostics, Tissue Diagnostics, Clinical Chemistry, and Other IVD Techniques. The Immunodiagnostics segment has dominated the market share of the global In-vitro diagnostics market. With the continuous development and progress of technology, the low-end immunodiagnosis field has achieved good localization results. However, the high-end immunodiagnosis field is still dominated by foreign giants and fuels the market demand for IVD in the future as well.

Application Overview in the Global In-vitro Diagnostics Market

Based on the application, the global In-Vitro Diagnostics market aggregated into Infectious Diseases, Cancer, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and Other Indications. Infectious diseases have the largest share in the in-vitro diagnostic market. It is mainly owing to the emerging conditions and outbreak of contagious diseases, causing epidemic fueled the market demand of IVD in the future as well.

End-use Overview in the Global In-vitro Diagnostics Market

Based on End-use, the global In-Vitro Diagnostics market classified into Standalone laboratories, Hospitals, Academic & Medical Schools, Point of Care Testing, and Others. The standalone laboratories have dominated the market share of the in-vitro diagnostic global market. It is mainly due to rising testing for new drugs, emerging viruses, and infectious diseases. Moreover, POCT will bolster its market demand in the future, owing to flexible and cost-effective medical devices that help in the diagnosis of conditions within a few minutes. Therefore, the market share of the global in-vitro diagnostics will fuel due to POCT rising demand.

Region Overview in the Global In-vitro Diagnostics Market

Based on geography, the global In-Vitro Diagnostics market segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The North America region will be expecting to witness the highest growth during the forecast period from 2021-2028. It is Owing to rising disposable income, emerging technological advancement, adoption of non-invasive devices, and healthcare facilities.

Global In-vitro Diagnostics Market: Competitive Landscape

Companies such as

Abbott Laboratories
Becton
Dickinson and Company
bioMÃ©rieux SA
Bio-Rad Laboratories Inc.
Danaher Corporation (Beckman Coulter, Inc.)
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
QIAGEN N.V.
Sysmex Corporation
Thermo Fisher Scientific Inc.
and others are key players in the global In-Vitro Diagnostics market.

1. Research Strategic Development

1.1. Market Modelling
1.2. Product Analysis
1.3. Market Trend and Economic Factors Analysis
1.4. Market Segmental Analysis
1.5. Geographical Mapping
1.6. Country Wise Segregation

2. Research Methodology

2.1. Identification of Target Market
2.2. Data Acquisition
2.3. Refining of Data/ Data Transformations
2.4. Data Validation through Primary Techniques
2.5. Exploratory Data Analysis
2.6. Graphical Techniques/Analysis
2.7. Quantitative Techniques/Analysis
2.8. Visual Result/Presentation

3. Executive Summary

4. Market Insights

4.1. Economic Factor Analysis

4.1.1. Drivers
4.1.2. Trends
4.1.3. Opportunities
4.1.4. Challenges

4.2. Competitors & Product Analysis
4.3. Regulatory Framework
4.4. Company market share analysis, 2020
4.5. Porterâ€™s Five forces analysis
4.6. New Investment Analysis
4.7. PESTEL Analysis

5. Global In-Vitro Diagnostics Market Overview

5.1. Market Size & Forecast, 2017-2028

5.1.1. Demand
5.1.1.1. By Value (USD Million)

5.2. Market Share & Forecast, 2017-2028

5.2.1. By Product Type
5.2.1.1. Reagents
5.2.1.2. Instruments
5.2.1.3. Software & Services
5.2.2. By Technique
5.2.2.1. Immunodiagnostics
5.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
5.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
5.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
5.2.2.1.1.4. Colorimetric Immunoassays (CIS)
5.2.2.2. Rapid Tests
5.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
5.2.2.4. Radioimmunoassay
5.2.2.5. Western Blot
5.2.2.6. Hematology
5.2.2.7. Molecular Diagnostics
5.2.2.7.1.1. Polymerase Chain Reaction (PCR)
5.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
5.2.2.7.1.3. Hybridization
5.2.2.7.1.4. DNA Diagnostics
5.2.2.7.1.5. Microarrays
5.2.2.7.1.6. Others
5.2.2.8. Tissue Diagnostics
5.2.2.9. Clinical Chemistry
5.2.2.9.1.1. Basic Metabolic Panel
5.2.2.9.1.2. Liver Panel
5.2.2.9.1.3. Lipid Profile
5.2.2.9.1.4. Thyroid Function Panel
5.2.2.9.1.5. Renal Profile
5.2.2.9.1.6. Electrolyte Panel
5.2.2.9.1.7. Specialty Chemicals
5.2.2.10. Other IVD Techniques
5.2.3. By Application
5.2.3.1. Infectious Diseases
5.2.3.2. Cancer
5.2.3.3. Cardiac Diseases
5.2.3.4. Immune System Disorders
5.2.3.5. Nephrological Diseases
5.2.3.6. Gastrointestinal Diseases
5.2.3.7. Other Indications
5.2.4. By End-user
5.2.4.1. Standalone Laboratory
5.2.4.2. Hospitals
5.2.4.3. Academic & Medical Schools
5.2.4.4. Point of Care Testing
5.2.4.5. Others
5.2.5. By Region
5.2.5.1. Europe
5.2.5.2. North America
5.2.5.3. Asia Pacific
5.2.5.4. South America
5.2.5.5. Middle East & Africa

6. Europe In-Vitro Diagnostics Market Overview

6.1. Europe In-Vitro Diagnostics Size & Forecast, 2017-2028

6.1.1. Demand
6.1.1.1. By Value (USD Million)

6.2. Europe In-Vitro Diagnostics Market Share & Forecast, 2017-2028

6.2.1. By Product Type
6.2.1.1. Reagents
6.2.1.2. Instruments
6.2.1.3. Software & Services
6.2.2. By Technique
6.2.2.1. Immunodiagnostics
6.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
6.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
6.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
6.2.2.1.1.4. Colorimetric Immunoassays (CIS)
6.2.2.2. Rapid Tests
6.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
6.2.2.4. Radioimmunoassay
6.2.2.5. Western Blot
6.2.2.6. Hematology
6.2.2.7. Molecular Diagnostics
6.2.2.7.1.1. Polymerase Chain Reaction (PCR)
6.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
6.2.2.7.1.3. Hybridization
6.2.2.7.1.4. DNA Diagnostics
6.2.2.7.1.5. Microarrays
6.2.2.7.1.6. Others
6.2.2.8. Tissue Diagnostics
6.2.2.9. Clinical Chemistry
6.2.2.9.1.1. Basic Metabolic Panel
6.2.2.9.1.2. Liver Panel
6.2.2.9.1.3. Lipid Profile
6.2.2.9.1.4. Thyroid Function Panel
6.2.2.9.1.5. Renal Profile
6.2.2.9.1.6. Electrolyte Panel
6.2.2.9.1.7. Specialty Chemicals
6.2.2.10. Other IVD Techniques
6.2.3. By Application
6.2.3.1. Infectious Diseases
6.2.3.2. Cancer
6.2.3.3. Cardiac Diseases
6.2.3.4. Immune System Disorders
6.2.3.5. Nephrological Diseases
6.2.3.6. Gastrointestinal Diseases
6.2.3.7. Other Indications
6.2.4. By End-user
6.2.4.1. Standalone Laboratory
6.2.4.2. Hospitals
6.2.4.3. Academic & Medical Schools
6.2.4.4. Point of Care Testing
6.2.4.5. Others
6.2.5. By Country
6.2.5.1. Germany
6.2.5.2. UK
6.2.5.3. France
6.2.5.4. Italy
6.2.5.5. Rest of Europe
6.2.6. Company Market Share (Top 3-5)
6.2.7. Economic Impact Study on Europe In-Vitro Diagnostics Market

7. North America In-Vitro Diagnostics Market Overview

7.1. North America In-Vitro Diagnostics Market Size & Forecast, 2017-2028

7.1.1. Demand
7.1.1.1. By Value (USD Million)

7.2. North America In-Vitro Diagnostics Market Share & Forecast, 2017-2028

7.2.1. By Product Type
7.2.1.1. Reagents
7.2.1.2. Instruments
7.2.1.3. Software & Services
7.2.2. By Technique
7.2.2.1. Immunodiagnostics
7.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
7.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
7.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
7.2.2.1.1.4. Colorimetric Immunoassays (CIS)
7.2.2.2. Rapid Tests
7.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
7.2.2.4. Radioimmunoassay
7.2.2.5. Western Blot
7.2.2.6. Hematology
7.2.2.7. Molecular Diagnostics
7.2.2.7.1.1. Polymerase Chain Reaction (PCR)
7.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
7.2.2.7.1.3. Hybridization
7.2.2.7.1.4. DNA Diagnostics
7.2.2.7.1.5. Microarrays
7.2.2.7.1.6. Others
7.2.2.8. Tissue Diagnostics
7.2.2.9. Clinical Chemistry
7.2.2.9.1.1. Basic Metabolic Panel
7.2.2.9.1.2. Liver Panel
7.2.2.9.1.3. Lipid Profile
7.2.2.9.1.4. Thyroid Function Panel
7.2.2.9.1.5. Renal Profile
7.2.2.9.1.6. Electrolyte Panel
7.2.2.9.1.7. Specialty Chemicals
7.2.2.10. Other IVD Techniques
7.2.3. By Application
7.2.3.1. Infectious Diseases
7.2.3.2. Cancer
7.2.3.3. Cardiac Diseases
7.2.3.4. Immune System Disorders
7.2.3.5. Nephrological Diseases
7.2.3.6. Gastrointestinal Diseases
7.2.3.7. Other Indications
7.2.4. By End-user
7.2.4.1. Standalone Laboratory
7.2.4.2. Hospitals
7.2.4.3. Academic & Medical Schools
7.2.4.4. Point of Care Testing
7.2.4.5. Others
7.2.5. By Country
7.2.5.1. US
7.2.5.2. Canada
7.2.5.3. Mexico
7.2.6. Company Market Share (Top 3-5)
7.2.7. Economic Impact Study on North America In-Vitro Diagnostics Market

8. Asia Pacific In-Vitro Diagnostics Overview

8.1. Asia Pacific In-Vitro Diagnostics Market Size & Forecast, 2017-2028

8.1.1. Demand
8.1.1.1. By Value (USD Million)

8.2. Asia Pacific In-Vitro Diagnostics Market Share & Forecast, 2017-2028

8.2.1. By Product Type
8.2.1.1. Reagents
8.2.1.2. Instruments
8.2.1.3. Software & Services
8.2.2. By Technique
8.2.2.1. Immunodiagnostics
8.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
8.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
8.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
8.2.2.1.1.4. Colorimetric Immunoassays (CIS)
8.2.2.2. Rapid Tests
8.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
8.2.2.4. Radioimmunoassay
8.2.2.5. Western Blot
8.2.2.6. Hematology
8.2.2.7. Molecular Diagnostics
8.2.2.7.1.1. Polymerase Chain Reaction (PCR)
8.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
8.2.2.7.1.3. Hybridization
8.2.2.7.1.4. DNA Diagnostics
8.2.2.7.1.5. Microarrays
8.2.2.7.1.6. Others
8.2.2.8. Tissue Diagnostics
8.2.2.9. Clinical Chemistry
8.2.2.9.1.1. Basic Metabolic Panel
8.2.2.9.1.2. Liver Panel
8.2.2.9.1.3. Lipid Profile
8.2.2.9.1.4. Thyroid Function Panel
8.2.2.9.1.5. Renal Profile
8.2.2.9.1.6. Electrolyte Panel
8.2.2.9.1.7. Specialty Chemicals
8.2.2.10. Other IVD Techniques
8.2.3. By Application
8.2.3.1. Infectious Diseases
8.2.3.2. Cancer
8.2.3.3. Cardiac Diseases
8.2.3.4. Immune System Disorders
8.2.3.5. Nephrological Diseases
8.2.3.6. Gastrointestinal Diseases
8.2.3.7. Other Indications
8.2.4. By End-user
8.2.4.1. Standalone Laboratory
8.2.4.2. Hospitals
8.2.4.3. Academic & Medical Schools
8.2.4.4. Point of Care Testing
8.2.4.5. Others
8.2.5. By Country
8.2.5.1. China
8.2.5.2. India
8.2.5.3. Japan
8.2.5.4. Australia
8.2.5.5. Rest of Asia Pacific
8.2.6. Company Market Share (Top 3-5)
8.2.7. Economic Impact Study on Asia Pacific In-Vitro Diagnostics Market

9. South America In-Vitro Diagnostics Market Overview

9.1. South America In-Vitro Diagnostics Market Size & Forecast, 2017-2028

9.1.1. Demand
9.1.1.1. By Value (USD Million)

9.2. South America In-Vitro Diagnostics Market Share & Forecast, 2017-2028

9.2.1. By Product Type
9.2.1.1. Reagents
9.2.1.2. Instruments
9.2.1.3. Software & Services
9.2.2. By Technique
9.2.2.1. Immunodiagnostics
9.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
9.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
9.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
9.2.2.1.1.4. Colorimetric Immunoassays (CIS)
9.2.2.2. Rapid Tests
9.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
9.2.2.4. Radioimmunoassay
9.2.2.5. Western Blot
9.2.2.6. Hematology
9.2.2.7. Molecular Diagnostics
9.2.2.7.1.1. Polymerase Chain Reaction (PCR)
9.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
9.2.2.7.1.3. Hybridization
9.2.2.7.1.4. DNA Diagnostics
9.2.2.7.1.5. Microarrays
9.2.2.7.1.6. Others
9.2.2.8. Tissue Diagnostics
9.2.2.9. Clinical Chemistry
9.2.2.9.1.1. Basic Metabolic Panel
9.2.2.9.1.2. Liver Panel
9.2.2.9.1.3. Lipid Profile
9.2.2.9.1.4. Thyroid Function Panel
9.2.2.9.1.5. Renal Profile
9.2.2.9.1.6. Electrolyte Panel
9.2.2.9.1.7. Specialty Chemicals
9.2.2.10. Other IVD Techniques
9.2.3. By Application
9.2.3.1. Infectious Diseases
9.2.3.2. Cancer
9.2.3.3. Cardiac Diseases
9.2.3.4. Immune System Disorders
9.2.3.5. Nephrological Diseases
9.2.3.6. Gastrointestinal Diseases
9.2.3.7. Other Indications
9.2.4. By End-user
9.2.4.1. Standalone Laboratory
9.2.4.2. Hospitals
9.2.4.3. Academic & Medical Schools
9.2.4.4. Point of Care Testing
9.2.4.5. Others
9.2.5. By Country
9.2.5.1. Brazil
9.2.5.2. Argentina
9.2.5.3. Rest of South America
9.2.6. Company Market Share (Top 3-5)
9.2.7. Economic Impact Study on South America In-Vitro Diagnostics Market

10. Middle East & Africa In-Vitro Diagnostics Market Overview

10.1. Middle East & Africa In-Vitro Diagnostics Market Size & Forecast, 2017-2028

10.1.1. Demand
10.1.1.1. By Value (USD Million)

10.2. Middle East & Africa In-Vitro Diagnostics Market Share & Forecast, 2018-2028

10.2.1. By Product Type
10.2.1.1. Reagents
10.2.1.2. Instruments
10.2.1.3. Software & Services
10.2.2. By Technique
10.2.2.1. Immunodiagnostics
10.2.2.1.1.1. Enzyme-Linked Immunosorbent Assay (ELISA)
10.2.2.1.1.2. Chemiluminescence Immunoassays (CLIAS)
10.2.2.1.1.3. Fluorescence Immunoassays (FIAS)
10.2.2.1.1.4. Colorimetric Immunoassays (CIS)
10.2.2.2. Rapid Tests
10.2.2.3. Enzyme-Linked ImmunoSpot Assays (ELISPOT)
10.2.2.4. Radioimmunoassay
10.2.2.5. Western Blot
10.2.2.6. Hematology
10.2.2.7. Molecular Diagnostics
10.2.2.7.1.1. Polymerase Chain Reaction (PCR)
10.2.2.7.1.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
10.2.2.7.1.3. Hybridization
10.2.2.7.1.4. DNA Diagnostics
10.2.2.7.1.5. Microarrays
10.2.2.7.1.6. Others
10.2.2.8. Tissue Diagnostics
10.2.2.9. Clinical Chemistry
10.2.2.9.1.1. Basic Metabolic Panel
10.2.2.9.1.2. Liver Panel
10.2.2.9.1.3. Lipid Profile
10.2.2.9.1.4. Thyroid Function Panel
10.2.2.9.1.5. Renal Profile
10.2.2.9.1.6. Electrolyte Panel
10.2.2.9.1.7. Specialty Chemicals
10.2.2.10. Other IVD Techniques
10.2.3. By Application
10.2.3.1. Infectious Diseases
10.2.3.2. Cancer
10.2.3.3. Cardiac Diseases
10.2.3.4. Immune System Disorders
10.2.3.5. Nephrological Diseases
10.2.3.6. Gastrointestinal Diseases
10.2.3.7. Other Indications
10.2.4. By End-user
10.2.4.1. Standalone Laboratory
10.2.4.2. Hospitals
10.2.4.3. Academic & Medical Schools
10.2.4.4. Point of Care Testing
10.2.4.5. Others
10.2.5. By Country
10.2.5.1. Saudi Arabia
10.2.5.2. UAE
10.2.5.3. South Africa
10.2.5.4. Rest of Middle East & Africa
10.2.6. Company Market Share (Top 3-5)
10.2.7. Economic Impact Study on Middle East & Africa In-Vitro Diagnostics Market

11. Competitor Analysis

11.1. Company Description
11.2. Financial Analysis
11.3. Key Products
11.4. Key Management Personnel
11.5. Contact Address
11.6. SWOT Analysis
11.7. Company Profile

11.7.1.1. Abbott Laboratories
11.7.1.2. Becton, Dickinson and Company
11.7.1.3. bioMÃ©rieux SA
11.7.1.4. Bio-Rad Laboratories, Inc.
11.7.1.5. Danaher Corporation (Beckman Coulter, Inc.)
11.7.1.6. F. Hoffmann-La Roche Ltd.
11.7.1.7. Johnson & Johnson
11.7.1.8. QIAGEN N.V.
11.7.1.9. Sysmex Corporation
11.7.1.10. Thermo Fisher Scientific, Inc
11.7.1.11. Other players

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1